Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Non-Current Debt: 2021-2025

Historic Non-Current Debt for Aytu Biopharma (AYTU) over the last 5 years, with Jun 2025 value amounting to $10.9 million.

  • Aytu Biopharma's Non-Current Debt rose 0.16% to $10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.4 million, marking a year-over-year increase of 0.16%. This contributed to the annual value of $10.9 million for FY2025, which is 0.17% up from last year.
  • Latest data reveals that Aytu Biopharma reported Non-Current Debt of $10.9 million as of FY2025, which was up 0.17% from $10.9 million recorded in FY2024.
  • In the past 5 years, Aytu Biopharma's Non-Current Debt registered a high of $14.7 million during FY2023, and its lowest value of $180,000 during FY2021.
  • In the last 3 years, Aytu Biopharma's Non-Current Debt had a median value of $10.9 million in 2025 and averaged $12.2 million.
  • Per our database at Business Quant, Aytu Biopharma's Non-Current Debt surged by 7,832.78% in 2022 and then declined by 26.07% in 2024.
  • Aytu Biopharma's Non-Current Debt (Yearly) stood at $180,000 in 2021, then soared by 7,832.78% to $14.3 million in 2022, then increased by 3.04% to $14.7 million in 2023, then decreased by 26.07% to $10.9 million in 2024, then climbed by 0.17% to $10.9 million in 2025.